Alcon has completed the acquisition of Aerie Pharmaceuticals, according to a press release.
Alcon used debt to fund the approximately $930 million transaction.
In the deal, Alcon acquired Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, Rhopressa (netarsudil ophthalmic solution) 0.02% and AR-15512, a phase 3 product candidate for dry eye disease, as well as a pipeline of ophthalmic pharmaceutical product candidates.
“Alcon has a rich history in the ophthalmic pharmaceutical space rooted in a deep understanding of eye care professionals,” Alcon CEO David